Adaptimmune Therapeutics ADAP are trading lower on Friday. The company late Thursday provided the full contents of its SITC abstract for its Phase 1 SURPASS trial.
Adaptimmune Therapeutics is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, NON-SMALL CELL LUNG CANCER, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.
Adaptimmune shares traded down 17.72% to $6.50 on Friday. The stock has a 52-week high of $13.40 and a 52-week low of 71 cents.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.